NCT00134004View on ClinicalTrials.gov

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
DRUG

cyclophosphamide

DRUG

fludarabine phosphate

DRUG

mycophenolate mofetil

DRUG

tacrolimus

PROCEDURE

allogeneic bone marrow transplantation

RADIATION

radiation therapy

Trial Locations (3)

30342

Blood and Marrow Transplant Program at Northside Hospital, Atlanta

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

19102-1192

Hahnemann University Hospital, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00134004 - Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | Biotech Hunter | Biotech Hunter